Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Gynecologic 1 Gastrointestinal 1 CNS 1

Conditions

Glioblastoma 202 Central Nervous System Neoplasms 122 Brain Neoplasms 107 Gliosarcoma 85 Glioma 68 Astrocytoma 63 Oligodendroglioma 34 Neuroblastoma 29 Medulloblastoma 20 Neoplasm Metastasis 19 Carcinoma, Non-Small-Cell Lung 15 Lung Neoplasms 14 Ependymoma 11 Diffuse Intrinsic Pontine Glioma 11 Breast Neoplasms 11 Meningeal Carcinomatosis 8 Neoplasms 7 Lymphoma 7 Squamous Cell Carcinoma of Head and Neck 6 Sarcoma 6 Optic Nerve Glioma 6 Neuroectodermal Tumors, Primitive 6 Lymphoma, Follicular 6 Head and Neck Neoplasms 6 Esthesioneuroblastoma, Olfactory 6 Burkitt Lymphoma 6 Spinal Cord Neoplasms 5 Salivary Gland Neoplasms 5 Rhabdoid Tumor 5 Recurrence 5

Interventions

Temozolomide 1 Sodium Chloride 1 Saline Solution 1 Radiotherapy 1 Injections 1 Ferrosoferric Oxide 1 Dexmedetomidine 1 3-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Hypoxia × Radiotherapy × CNS × Clear all

NCT06477939 2024-06-27

THREE-GLEES

Institut de cancérologie Strasbourg Europe

Phase 3 Not yet recruiting

Hypoxia, Brain Neoplasms, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡